Constellation Pharmaceuticals Inc. [NASDAQ: CNST] closed the trading session at $19.62 on 10/30/20. The day’s price range saw the stock hit a low of $18.56, while the highest price level was $20.79. The company report on October 29, 2020 that Constellation Pharmaceuticals Announces Third-Quarter 2020 Financial Results.
MANIFEST data update planned for the American Society of Hematology (ASH) meeting in December .
Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced its third-quarter 2020 financial results. The Company also provided updates on its product candidates CPI-0610 and CPI-0209.
The stocks have a year to date performance of -58.35 percent and weekly performance of -18.93 percent. The stock has been moved at -48.42 percent over the last six months. The stock has performed -14.17 percent around the most recent 30 days and changed -30.79 percent over the most recent 3-months.
If compared to the average trading volume of 558.48K shares, CNST reached to a volume of 1370232 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Constellation Pharmaceuticals Inc. [CNST]:
Oppenheimer have made an estimate for Constellation Pharmaceuticals Inc. shares, keeping their opinion on the stock as Perform, with their previous recommendation back on September 08, 2020. The new note on the price target was released on July 20, 2020, representing the official price target for Constellation Pharmaceuticals Inc. stock. Previously, the target price had yet another raise to $36, while JMP Securities analysts kept a Mkt Perform rating on CNST stock. On May 07, 2020, analysts increased their price target for CNST shares from 50 to 75.
The Average True Range (ATR) for Constellation Pharmaceuticals Inc. is set at 1.78 The Price to Book ratio for the last quarter was 2.11, with the Price to Cash per share for the same quarter was set at 10.80.
CNST stock trade performance evaluation
Constellation Pharmaceuticals Inc. [CNST] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -18.93. With this latest performance, CNST shares dropped by -14.17% in over the last four-week period, additionally sinking by -48.42% over the last 6 months – not to mention a rise of 42.07% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for CNST stock in for the last two-week period is set at 40.45, with the RSI for the last a single of trading hit 35.46, and the three-weeks RSI is set at 42.02 for Constellation Pharmaceuticals Inc. [CNST]. The present Moving Average for the last 50 days of trading for this stock 21.80, while it was recorded at 21.46 for the last single week of trading, and 30.21 for the last 200 days.
Constellation Pharmaceuticals Inc. [CNST]: An insightful look at the core fundamentals
Constellation Pharmaceuticals Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 15.80 and a Current Ratio set at 15.80.
Earnings per share (EPS) analysis for Constellation Pharmaceuticals Inc. [CNST] stock
With the latest financial reports released by the company, Constellation Pharmaceuticals Inc. posted -0.69/share EPS, while the average EPS was predicted by analysts to be reported at -0.69/share. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for CNST.
Constellation Pharmaceuticals Inc. [CNST]: Insider Ownership positions
There are presently around $1,025 million, or 99.53% of CNST stock, in the hands of institutional investors. The top three institutional holders of CNST stocks are: SVENNILSON PETER with ownership of 6,051,376, which is approximately 0% of the company’s market cap and around 0.10% of the total institutional ownership; WELLINGTON MANAGEMENT GROUP LLP, holding 4,400,765 shares of the stock with an approximate value of $86.34 million in CNST stocks shares; and VR ADVISER, LLC, currently with $78.81 million in CNST stock with ownership of nearly 0% of the company’s market capitalization.
107 institutional holders increased their position in Constellation Pharmaceuticals Inc. [NASDAQ:CNST] by around 18,172,750 shares. Additionally, 30 investors decreased positions by around 5,659,397 shares, while 14 investors held positions by with 28,422,643 shares. The mentioned changes placed institutional holdings at 52,254,790 shares, according to the latest SEC report filing. CNST stock had 48 new institutional investments in for a total of 5,483,755 shares, while 14 institutional investors sold positions of 2,575,868 shares during the same period.